Cargando…

Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [(18)F]PSMA-1007, in a Subcutaneous Prostate Cancer Xenograft Mouse Model

[Image: see text] Several radiolabeled prostate-specific membrane antigen (PSMA)-targeted agents have been developed for detecting prostate cancer, using positron emission tomography imaging and targeted radionuclide therapy. Among them, [(18)F]PSMA-1007 has several advantages, including a comparati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Su Bin, Song, In Ho, Kim, Seon Yoo, Ko, Hae Young, Kil, Hee Seup, Chi, Dae Yoon, Giesel, Frederik L., Kopka, Klaus, Hoepping, Alexander, Chun, Joong-Hyun, Park, Hyun Soo, Yun, Mijin, Kim, Sang Eun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906735/ https://www.ncbi.nlm.nih.gov/pubmed/36583623 http://dx.doi.org/10.1021/acs.molpharmaceut.2c00788

Ejemplares similares

Biodistribution and internal radiation dosimetry of a companion diagnostic radiopharmaceutical, [(68)Ga]PSMA-11, in subcutaneous prostate cancer xenograft model mice
por: Kim, Su Bin, et al.
Publicado: (2021)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

Automated [(18)F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination
por: Naka, Sadahiro, et al.
Publicado: (2020)

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
por: Giesel, Frederik L., et al.
Publicado: (2016)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

Procedures for the GMP-Compliant Production and Quality Control of [(18)F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer
por: Cardinale, Jens, et al.
Publicado: (2017)

Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

PSMA-1007 Uptake in Ganglia of the Sympathetic Trunk and Its Intra-individual Reproducibility
por: Mamlins, E., et al.
Publicado: (2022)

An Explorative Study of the Incidental High Renal Excretion of [(18)F]PSMA-1007 for Prostate Cancer PET/CT Imaging
por: Allach, Youssra, et al.
Publicado: (2022)

Novel Preclinical and Radiopharmaceutical Aspects of [(68)Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
por: Eder, Matthias, et al.
Publicado: (2014)

Intra-Individual Comparison of Physiologic [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis
por: Novruzov, Emil, et al.
Publicado: (2023)

High detection rate in [(18)F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
por: Watabe, Tadashi, et al.
Publicado: (2021)

Intraindividual comparison of [(68) Ga]-Ga-PSMA-11 and [(18)F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis
por: Hoberück, Sebastian, et al.
Publicado: (2021)

Biokinetics and dosimetry of (18)F‐PSMA‐1007 in patients with prostate cancer
por: Hvittfeldt, Erland, et al.
Publicado: (2022)

Skeletal (18)F-PSMA-1007 uptake in prostate cancer patients
por: Janssen, Jorinde, et al.
Publicado: (2023)

Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach
por: Lahnif, Hanane, et al.
Publicado: (2021)

Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov
por: Zippel, Claus, et al.
Publicado: (2020)

Phase III Study of (18)F-PSMA-1007 Versus (18)F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study
por: Olivier, Pierre, et al.
Publicado: (2023)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
por: Iversen, Peter, et al.
Publicado: (2022)

Detecting and Locating the Site of Local Relapse Using (18)F-PSMA-1007 Imaging After Primary Treatment of 135 Prostate Cancer Patients—Potential Impact on PSMA-Guided Radiation Therapy
por: Koerber, S. A., et al.
Publicado: (2022)

Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
por: Sprute, Katharina, et al.
Publicado: (2021)

(18)F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report
por: Wang, Long, et al.
Publicado: (2021)

MIB Guides: Preclinical radiopharmaceutical dosimetry
por: Carter, Lukas M., et al.
Publicado: (2023)

Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [(18)F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer
por: Katzschmann, Ines, et al.
Publicado: (2021)

PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
por: Ramnaraign, Brian, et al.
Publicado: (2023)

Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007
por: Robu, Stephanie, et al.
Publicado: (2018)

Non-prostate uptake on (18)F-PSMA-1007 PET/CT: a case of myeloma
por: Veerasuri, Sowmya, et al.
Publicado: (2020)

Dose-reduced [(18)F]PSMA-1007 PET is feasible for functional imaging of the renal cortex
por: Valind, Kristian, et al.
Publicado: (2021)

[(18)F]F-PSMA-1007 Radiolabelling without an On-Site Cyclotron: A Quality Issue
por: Di Iorio, Valentina, et al.
Publicado: (2021)

(18)F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis
por: Ferrari, Matteo, et al.
Publicado: (2021)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Pharmaceuticals—Special Issue on Radiopharmaceutical Chemistry between Imaging and Endoradiotherapy
por: Kopka, Klaus
Publicado: (2014)

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives
por: El Fakiri, Mohamed, et al.
Publicado: (2021)

Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Optimization of [(18)F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer
por: Trägårdh, Elin, et al.
Publicado: (2020)

Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET
por: Maurer, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ln5rjrm9ce7cn5vs5oelqjuddk